Selected article for: "primer strand and template strand"
Author: Wanchao Yin; Chunyou Mao; Xiaodong Luan; Dan-Dan Shen; Qingya Shen; Haixia Su; Xiaoxi Wang; Fulai Zhou; Wenfeng Zhao; Minqi Gao; Shenghai Chang; Yuan-Chao Xie; Guanghui Tian; He-Wei Jiang; Sheng-Ce Tao; Jingshan Shen; Yi Jiang; Hualiang Jiang; Yechun Xu; Shuyang Zhang; Yan Zhang; H. Eric Xu
Title: Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir
  • Document date: 2020_4_9
    • ID: 7v7pzclb_9
    Snippet: At the 3' end of the primer strand is Remdesivir monophosphate (RMP) ( Figure 3C and 4D), which is covalently incorporated into the primer strand at the +1 position ( Figure 4E ). Additional nucleotides at +2 and +3 positions from the template strand from interactions with residues from the back from the index finger subdomain ( Figure 4B ). Despite the presence of excess amount of RTP in complex assembly, only a single RMP is assembled into the .....
    Document: At the 3' end of the primer strand is Remdesivir monophosphate (RMP) ( Figure 3C and 4D), which is covalently incorporated into the primer strand at the +1 position ( Figure 4E ). Additional nucleotides at +2 and +3 positions from the template strand from interactions with residues from the back from the index finger subdomain ( Figure 4B ). Despite the presence of excess amount of RTP in complex assembly, only a single RMP is assembled into the primer strand. Thus, Remdesivir, like many nucleotide analog prodrugs, inhibits the viral RdRp activity indirectly through non-obligate RNA chain termination, a mechanism that requires the conversion of the parent drug to the active triphosphate form (27) .

    Search related documents:
    Co phrase search for related documents
    • active triphosphate form and chain termination: 1, 2, 3, 4
    • active triphosphate form and RdRp activity: 1, 2, 3
    • active triphosphate form and RNA chain termination: 1, 2
    • active triphosphate form and template strand: 1, 2
    • active triphosphate form and triphosphate form: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
    • additional nucleotide and triphosphate form: 1
    • analog prodrug and nucleotide analog prodrug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • analog prodrug and parent drug: 1
    • analog prodrug and Remdesivir monophosphate: 1
    • analog prodrug and triphosphate form: 1
    • chain termination and RdRp activity: 1, 2
    • chain termination and Remdesivir monophosphate: 1, 2, 3
    • chain termination and RMP Remdesivir monophosphate: 1, 2
    • chain termination and RNA chain termination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • chain termination and template strand: 1, 2, 3
    • chain termination and triphosphate form: 1, 2, 3, 4, 5, 6, 7, 8
    • complex assembly and primer strand: 1
    • complex assembly and primer strand end: 1
    • complex assembly and RdRp activity: 1